
|Articles|March 1, 2007
FDA grants orphan status to two Lux products
The FDA has granted orphan drug designation to two of Lux Bioscience's investigational therapies.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: EU-ROP Registry bridges borders for real-world insight
2
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage
3
FLORetina 2025: Enrico Borrelli on reframing retinal disease through the lens of choroidal health
4
FLORetina 2025: New horizons in research and risk management for ROP
5













































